Association Between Drug Exposure and Occurrence of Parkinsonism in Korea: A Population-Based Case-Control Study
Background: Although drug-induced parkinsonism is reversible in most cases, some patients can suffer from persistent/recurrent symptoms. Therefore, prevention is the most efficient way to manage drug-induced parkinsonism. However, there is a paucity of studies exploring the relationship between parkinsonism and drug exposure. Objective: To examine the association between drug exposure and the risk of parkinsonism using Korean population-based data. Methods: We conducted a matched case-control study using the National Health Insurance Service—National Sample Cohort database. Cases and controls were defined as individuals with and without parkinsonism, respectively, between 2007 and 2013. Cases and controls were matched for sex, age group, income, type of insurance, and Charlson comorbidity index. Drug exposures, including propulsives, antipsychotics, and flunarizine, were identified at 1 year before the first date of parkinsonism and stratified by recency and cumulative dose. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% CIs. Results: We identified 5496 cases and 5496 controls. ORs for current use group of propulsives, antipsychotics, and flunarizine compared with those of the never use group were 2.812 (95% CI = 2.466-3.206), 3.009 (95% CI = 1.667-5.431), and 4.950 (95% CI = 2.711-9.037), respectively. ORs were greater in those more recently exposed and those exposed to higher cumulative doses. Conclusion and Relevance: At the population level, use of propulsives, antipsychotics, and flunarizine had a significant association with the increased risk of parkinsonism, depending on recency and cumulative dose. Drugs associated with parkinsonism should be used with careful monitoring to prevent drug-induced parkinsonism.
Top-30
Journals
|
1
2
3
|
|
|
Frontiers in Pharmacology
3 publications, 11.54%
|
|
|
Journal of Clinical Medicine
2 publications, 7.69%
|
|
|
International Journal of Environmental Research and Public Health
1 publication, 3.85%
|
|
|
Medicines
1 publication, 3.85%
|
|
|
Frontiers in Psychiatry
1 publication, 3.85%
|
|
|
Neurological Sciences
1 publication, 3.85%
|
|
|
Egyptian Journal of Neurology, Psychiatry and Neurosurgery
1 publication, 3.85%
|
|
|
European Child and Adolescent Psychiatry
1 publication, 3.85%
|
|
|
Journal of Drug Delivery Science and Technology
1 publication, 3.85%
|
|
|
Journal of the American Geriatrics Society
1 publication, 3.85%
|
|
|
Pharmacology Research and Perspectives
1 publication, 3.85%
|
|
|
Pharmacotherapy
1 publication, 3.85%
|
|
|
Risk Management and Healthcare Policy
1 publication, 3.85%
|
|
|
Canadian Journal of Neurological Sciences
1 publication, 3.85%
|
|
|
Meditsinskiy sovet = Medical Council
1 publication, 3.85%
|
|
|
Nevrologiya, Neiropsikhiatriya, Psikhosomatika
1 publication, 3.85%
|
|
|
Pharmacoepidemiology and Drug Safety
1 publication, 3.85%
|
|
|
EClinicalMedicine
1 publication, 3.85%
|
|
|
Expert Opinion on Drug Safety
1 publication, 3.85%
|
|
|
Neuroglia
1 publication, 3.85%
|
|
|
Anesthesiology and Pain Medicine
1 publication, 3.85%
|
|
|
Cureus
1 publication, 3.85%
|
|
|
Asian Journal of Surgery
1 publication, 3.85%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
|
|
|
MDPI
5 publications, 19.23%
|
|
|
Frontiers Media S.A.
4 publications, 15.38%
|
|
|
Springer Nature
4 publications, 15.38%
|
|
|
Wiley
4 publications, 15.38%
|
|
|
Elsevier
3 publications, 11.54%
|
|
|
Taylor & Francis
2 publications, 7.69%
|
|
|
Cambridge University Press
1 publication, 3.85%
|
|
|
Remedium, Ltd.
1 publication, 3.85%
|
|
|
IMA Press, LLC
1 publication, 3.85%
|
|
|
Brieflands
1 publication, 3.85%
|
|
|
1
2
3
4
5
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.